Clinical Study
Immunosuppression Adversely Affects TST but Not IGRAs in Patients with Psoriasis or Inflammatory Musculoskeletal Diseases
Table 5
The univariate analysis of the TB risk factors with a positive outcome for TST.
| | Variable | All patients | TST cut-off 10 mm | | | | OR | Significance | | Positive | (95% CI) | < |
| | Age, mean (test neg. mean) | 57.5 | 53.0 (62.4) | 0.95 (0.92–0.99) | 0.006 | | Sex, female, (%) | 65 (59.6) | (47.7) | 0.2 (0.06–0.5) | 0.002 | | BCG vaccination, (%) | 46 (42.2) | 23 (52.3) | 2.4 (1.0–6.3) | 0.06 | | Born in TB-endemic country, (%) | 12 (11.0) | 8 (18.2) | 7.8 (0.9–65.5) | 0.06 | | Contact with TB, (%) | 15 (13.8) | 5 (11.4) | 0.5 (0.2–1.8) | 0.6 | | Previous TB history, ( %) | 12 (11.0) | 6 (13.6) | 0.8 (0.2–2.7) | 0.7 | | Any risk factor for LTBI, (%) | 33 (30.3) | 15 (34.1) | 0.9 (0.4–2.3) | 0.9 | | Positive chest X-ray, (%) | 8 (7.3) | 2 (4.9) | 0.5 (0.1–3.1) | 0.5 | | Group 1, (%) | 21 (19.3) | 9 (69.2) | 2.1 (0.6–7.3) | 0.3 | | Group 2, (%) | 71 (65.1) | 34 (54.8) | 1.0 (0.6–1.7) | 1.0 | | Group 3, (%) | 17 (15.6) | 1 (20.0) | 0.5 (0.2–1.0) | 0.06 | | Corticosteroids, (%) | 38 (34.9) | 9 (20.5) | 0.3 (0.1–0.9) | 0.03 | | Cytostatic treatment, (%) | 48 (44.0) | 24 (54.5) | 1.9 (0.8–4.6) | 0.2 | | Biological treatment, (%) | 6 (5.5) | 2 (4.5) | 0.5 (0.1–3.3) | 0.5 |
|
|
